Filter by
Documents (84)
RSSShowing results 60 to 80
Key performance indicators (KPIs) to monitor the European clinical trials environment (1-31 March 2023, edition 12)
Key performance indicators (KPIs) to monitor the European clinical trials environment (1-28 February 2023, edition 11)
Key performance indicators (KPIs) to monitor the European clinical trials environment (1-31 January 2023, edition 10)
Key performance indicators (KPIs) to monitor the European clinical trials environment (1-31 December 2022, edition 9)
Key performance indicators (KPIs) to monitor the European clinical trials environment (1-30 November 2022, edition 8)
Key performance indicators (KPIs) to monitor the European clinical trials environment (1-31 October 2022, edition 7)
Key performance indicators (KPIs) to monitor the European clinical trials environment (1-30 September 2022, edition 6)
Key performance indicators (KPIs) to monitor the European clinical trials environment (1-31 August 2022, edition 5)
Key performance indicators (KPIs) to monitor the European clinical trials environment (1-31 July 2022, edition 4)
Key performance indicators (KPIs) to monitor the European clinical trials environment (1-30 June 2022, edition 3)
Key performance indicators (KPIs) to monitor the European clinical trials environment (1-31 May 2022, edition 2)
Key performance indicators (KPIs) to monitor the European clinical trials environment (31 January – 30 April 2022, edition 1)
Complex clinical trials – questions and answers
Recommendation paper on decentralised elements in clinical trials
Annex I - Guidance document on how to approach the protection of personal data and commercially confidential information while using the Clinical Trials Information System (CTIS) Version 2
Guidance document on how to approach the protection of personal data and commercially confidential information while using the Clinical Trials Information System (CTIS) Version 2
Outcome of public consultation on ACT EU MSP participation and priorities for discussion
The report on the outcome of a public consultation where the European Medicines Agency invited stakeholders to provide input on the ACT EU MSP concept paper, priority topics for the MSP and to express their interest in participating.
Advice on medicines for human use in the EU medicines regulatory network
Q&A on the protection of commercially confidential information and personal data while using CTIS
Updated guidance is available for CTIS users on how to protect personal data and commercially confidential information.
Accelerating clinical trials in the EU (ACT EU) - Delivering an EU clinical trials transformation initiative
